Quest Diagnostics Inc
DGX · NYSE · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2016–FY2025
- History
- 10 years
- Latest filing
- 10-K · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- December
- Last updated
- Feb 2026
Headline figures
Quest Diagnostics Inc at a glance
In FY2025, Quest Diagnostics Inc reported revenue of USD 11,035 mn, EBITDA of USD 2,126 mn, EBITDA margin of 19.3%.
| USD mn | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 9,872 | 11,035 | |||
| EBITDA | 1,839 | 2,126 | |||
| EBITDA margin | 18.6% | 19.3% | |||
| Free cash flow | 909 | 1,359 | |||
| ROIC | 9.5% | 10.0% |
The full 10-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas